Biotech | March 12, 2022
BioPharma’s Herceptin biosimilar Phase 3 results positive
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers releases guidelines for the scheme
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Routine tests undertaken by women dropped by 35% in 2020
As an initial remote monitoring diagnostic approach, Philips BioTel Heart MCOT detected 4.6 times more patients with atrial fibrillation compared to implantable loop recorder alone
Subscribe To Our Newsletter & Stay Updated
